Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Oct;119(8):911-912.
doi: 10.1038/s41416-018-0175-x. Epub 2018 Oct 17.

Combination VEGFR/immune checkpoint inhibitor therapy: a promising new treatment for renal cell carcinoma

Chung-Han Lee  1 , Robert Motzer  2
Affiliations
Editorial

Combination VEGFR/immune checkpoint inhibitor therapy: a promising new treatment for renal cell carcinoma

Chung-Han Lee et al. Br J Cancer. 2018 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

C.-H.L.: Consulting (Exelixis, Eisai), and Research Funds to the Institute (BMS, Exelixis, Pfizer, Calithera, Eisai). R.J.M.: Consulting (Novartis, Pfizer, Eisai, Exelixis), and research funds to the institute (Novartis, Pfizer, Eisai, Exelixis, BMS, Genetech/Roche).

Comment on

References

    1. Chowdhury S, et al. A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab. (PEM) Patients (pts) Adv. Ren. Cell Carcinoma. 2017;35:4506.
    1. Amin, A. et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC), Journal of Clinical Oncology. 32, (suppl.), abstr. 5010 (2014).
    1. Atkins MB, et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol. 2018;19:405–415. doi: 10.1016/S1470-2045(18)30081-0. - DOI - PMC - PubMed
    1. Hutson TE, et al. Comparing the results of this Phase 1b trial to the results of others may not be feasible at this early stage. Lancet Oncol. 2013;14:1287–1294. doi: 10.1016/S1470-2045(13)70465-0. - DOI - PubMed
    1. Motzer RJ, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 2015;373:1803–1813. doi: 10.1056/NEJMoa1510665. - DOI - PMC - PubMed